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Alpha-synuclein (a-Syn) is a key protein involved in Parkinson's disease (PD) pathology.
PD is characterized by the loss of dopaminergic neuronal cells in the substantia nigra
pars compacta and the abnormal accumulation and aggregation of a-Syn in the form of
Lewy bodies and Lewy neurites. More precisely, the aggregation of a-Syn is associated
with the dysfunctionality and degeneration of neurons in PD. Moreover, mutations in the
SNCA gene, which encodes a-Syn, cause familial forms of PD and are the basis of
sporadic PD risk. Given the role of the a-Syn protein in the pathology of PD, animal models
that reflect the dopaminergic neuronal loss and the widespread and progressive formation
of a-Syn aggregates in different areas of the brain constitute a valuable tool. Indeed,
animal models of PD are important for understanding the molecular mechanisms of the
disease and might contribute to the development and validation of new therapies. In the
absence of animal models that faithfully reproduce human PD, in recent years, numerous
animal models of PD based on a-Syn have been generated. In this review, we summarize
the main features of the a-Syn pre-formed fibrils (PFFs) model and recombinant adeno-
associated virus vector (rAAV) mediated a-Syn overexpression models, providing a
detailed comparative analysis of both models. Here, we discuss how each model has
contributed to our understanding of PD pathology and the advantages and weakness of
each of them.
Significance: Here, we show that injection of a-Syn PFFs and overexpression of a-Syn
mediated by rAAV lead to a different pattern of PD pathology in rodents. First, a-Syn PFFs
models trigger the Lewy body-like inclusions formation in brain regions directly interconnected
with the injection site, suggesting that there is an inter-neuronal transmission of the a-Syn
pathology. In contrast, rAAV-mediated a-Syn overexpression in the brain limits the a-Syn
aggregates within the transduced neurons. Second, phosphorylated a-Syn inclusions
obtained with rAAV are predominantly nuclear with a punctate appearance that becomes
diffuse along the neuronal fibers, whereas a-Syn PFFs models lead to the formation of
cytoplasmic aggregates of phosphorylated a-Syn reminiscent of Lewy bodies and Lewy
neurites.
Keywords: Lewy body pathology, a-Syn pre-formed fibrils, a-Syn AVV-viral particles, prion-like propagation, Braak
hypothesis, a-Syn aggregationin.org April 2020 | Volume 11 | Article 3561
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Parkinson's Disease (PD) is the second most common
neurodegenerative disorder after Alzheimer's disease.
Currently, PD affects 1%–2% of people over the age of 60
years, rising to 4% at age 80 years (Rizek et al., 2016). PD is
mainly characterized by the progressive loss of dopaminergic
neurons of the substantia nigra that project to the striatum (Xu
and Pu, 2016). The deficiency of dopamine in the striatum leads
to the development of the classic motor symptoms of PD,
including bradykinesia, resting tremor, muscular rigidity, and
postural instability. In addition to motor symptomatology, non-
motor manifestations, such as autonomic dysfunction, olfactory
impairment, mood disorders (i.e., depression and anxiety),
cognitive deficits, or sleep disturbances are also frequently
present in PD. Most of these symptoms appear even before the
motor symptoms and have a serious impact on the quality of life
of patients (Kalia and Lang, 2015; Schapira et al., 2017). Because
the PD motor symptoms emerge when the striatal dopamine
levels have decreased by 60%–80% (Dauer and Przedborski,
2003), the study of PD non-motor symptoms is important to
identify early biomarkers as well as targets to develop disease-
modifying therapies that slow or prevent the progression
of neurodegeneration.
The neuropathological mechanisms underlying non-motor
symptoms of PD are still poorly understood, but growing
evidence suggests that the evolution of these symptoms may
arise from the disruption of both dopaminergic and non-
dopaminergic systems, and the involvement of diverse
structures outside the nigrostriatal system (Jellinger, 2017;
Schapira et al., 2017). Besides the dopamine, the further key
neurotransmission systems that have been described to be
involved in the pathogenesis of PD are the noradrenergic
system of locus coeruleus, the serotonergic system of the dorsal
raphe nuclei, and the cholinergic system of the nucleus basalis of
Meynert and the pedunculopontine nucleus (Qamar et al., 2017).
Since the relative contribution of each of these pathways to
motor and non-motor symptoms has only been partially
explored, additional research is needed to fully understand
their involvement in the clinical and pathological features of
the disease.
The neuropathological hallmark of PD is the abnormal
accumulation and aggregation of alpha synuclein protein (a-
Syn) in form of Lewy bodies and Lewy neurites (Xu and Pu,
2016). It is well established that pathological aggregation of a-
Syn is a common feature of several neurodegenerative diseases
including PD, dementia with Lewy bodies (DLB) and multiple
system atrophy (MSA), that are collectively referred as
synucleinopathies (Goedert et al., 2017). a-Syn is a protein
with remarkable conformational plasticity since it can adopt a
wide range of structural conformations (oligomers, protofibrils
and fibrils; Deleersnijder et al., 2013; Mehra et al., 2019). Each a-
Syn conformation displays distinct properties in terms of
neurotoxicity, stability and seeding and propagation ability. It
has been proposed that the existence of structurally distinct a-
Syn assemblies or a-Syn “strains” may contribute to explain the
clinical-pathological heterogeneity among synucleinopathies andFrontiers in Pharmacology | www.frontiersin.org 2help to develop strain-specific medications (Melki, 2015;
Peelaerts et al., 2015; Candelise et al., 2019).
Parallel to deficits in both dopaminergic and non-
dopaminergic neurotransmission systems, the appearance of
PD non-motor symptoms is also attributed to the sequential
development of Lewy bodies in different brain regions, including
the olfactory bulb, the dorsal motor nucleus of the vagal nerve,
locus coeruleus, raphe nucleus, basal nucleus of Meynert and
pedunculopontine nucleus (Braak et al., 2003; Braak et al., 2004;
Schindlbeck and Eidelberg, 2019). Both hypotheses are not
mutually exclusive, since sequential distribution of Lewy bodies
through the brain may alter various neurotransmission pathways
that may be the basis of non-motor manifestations. To date, the
etiology of PD remains unknown, but cumulative evidence
suggests that the presence of intraneuronal inclusions of a-Syn
affects the functional integrity of neurons, ultimately causing
their death. It has been demonstrated that a-Syn aggregates can
induce neuronal toxicity leading to neuronal death by multiple
mechanisms, including mitochondrial dysfunction, lysosomal
impairment, membrane disturbance, endoplasmic reticulum
stress, and synaptic dysfunction (reviewed in Roberts and
Brown, 2015; Xu and Pu, 2016; Zhang et al., 2018; Zhang
et al., 2019). However, although the Lewy pathology is
commonly observed in PD, there remains much debate over
whether a-Syn aggregation is a key feature for the development
and progression of the disease. Two observations contribute to
this debate: first, there is solid evidence that not all cases of
parkinsonism are characterized by the presence of a-Syn
inclusions—several studies have reported that PD patients
carrying familial mutations in Parkin gene, and some of those
with the LRRK2 G2019S mutation, show neuronal degeneration
but do not develop Lewy bodies (Gaig et al., 2009; Johansen et al.,
2018) and, second, postmortem analysis reflect that Lewy bodies
and Lewy neurites may be present in the absence of clinical PD
symptoms (Parkkinen et al., 2005). Strengths and limitations of
the evidence that correlate the aggregation of a-Syn with the
progression of PD pathology will be addressed throughout
the review.THE ROLE OF ALPHA-SYNUCLEIN IN PD
PATHOLOGY
a-Syn is a small protein encoded by the SNCA gene that is
abundantly expressed in the presynaptic terminals of the central
nervous system. The exact function of a-Syn remains largely
unknown, although mounting evidence supports the notion that
a-Syn is involved in synaptic plasticity and neurotransmitter
release (Burré et al., 2010; Venda et al., 2010). Likewise, recent
studies have shown that neuronal/synaptic activity regulates
dynamically the physiological release of endogenous a-Syn, so
an elevated neuronal activity increases the release of a-Syn
(Yamada and Iwatsubo, 2018). Several lines of evidence
demonstrate the pathogenic role of a-Syn in PD: 1) point
mutations (A30P, E46K, H50Q, G51D, A53T, and A53E) and
duplication or triplication of the SNCA gene cause autosomalApril 2020 | Volume 11 | Article 356
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et al., 2004); 2) polymorphic variants of the SNCA gene
constitute an important risk factor for developing idiopathic
PD (Nalls et al., 2014); and 3) a-Syn is the major component of
Lewy bodies (Spillantini et al., 1997; Wakabayashi et al., 2013).
Under normal conditions, native a-Syn exists in a dynamic
equilibrium between unfolded monomers and a-helically folded
tetramers with a low propensity to aggregation (Lashuel et al.,
2013). The decline of the tetramer:monomer ratio and the
consequent increase in the level of a-Syn unfolded monomers
favor its aggregation (Nuber et al., 2018). The aggregation
process of a-Syn involves a conformational change whereby it
adopts a b-sheet-rich structure that facilitates its aggregation into
oligomers, protofibrils, and insoluble fibrils that finally
accumulate in Lewy bodies. There is an intense debate about
what a-Syn species are cytotoxic. Although both oligomeric and
fibrillar species of a-Syn have been shown to be toxic, recent
studies suggest that oligomers and protofibrils, forming during
the initial stages of the aggregation process, are the potent
neurotoxic species causing cell death in PD. Conversely, a-Syn
fibrils appear to be the most efficient species at propagating, thus
contributing to the spread and progression of the disease (Alam
et al., 2019; Mehra et al., 2019). Most of studies that confirm the
pathogenic effects of different a-Syn assemblies have used in
vitro formed species; so the extent to which these oligomers
recapitulate the structure and properties of those found in brain
tissue from PD patients remains unclear (Bengoa-Vergniory
et al., 2017). Mutations, post-translational modifications, an
imbalance between synthesis and degradation of a-Syn, and
environmental factors influence the aggregation propensity of a-
Syn. The A53T mutation was the first to be documented, and it is
associated with an early-onset PD (Polymeropoulos et al., 1997).
The E46K mutation predisposes to the development of severe
parkinsonism with dementia and a large number of Lewy bodies
that are widely distributed (Zarranz et al., 2004). Both mutations
alter the a-Syn protein structure, which facilitates its aggregation
(Li et al, 2001; Greenbaum et al., 2005; Tosatto et al., 2015).
a-Syn undergoes various post-translational modifications,
such as phosphorylation, truncation, ubiquitination, and
nitration. Phosphorylation of a-Syn at the serine 129 residue is
one of the major pathological markers of PD; 90% of a-Syn is
phosphorylated in the brain of patients with PD while only 4% of
a-Syn is phosphorylated in healthy brains (Oueslati, 2016;
Ghosh et al., 2017). However, there is a great controversy over
whether phosphorylation has an active role in the a-Syn
aggregation or if it is a response mechanism of cells to try to
label and eliminate toxic species of a-Syn (Oueslati, 2016). Smith
et al. (2005) proposed that phosphorylation of a-Syn promotes
the formation of cytoplasmic inclusions in some cell culture
models (Smith et al., 2005). Nevertheless, Oueslati et al. (2013)
show that phosphorylation of a-Syn induced by polo-like kinase
2 has no effect on the aggregation and regulates a-Syn clearance
via the lysosomal autophagy pathway (Oueslati et al., 2013).
Additional lines of evidence show crosstalk between
phosphorylation and a-Syn degradation. The inhibition of the
ubiquitin-proteasome system (Chau et al., 2009) or theFrontiers in Pharmacology | www.frontiersin.org 3autophagy-lysosomal pathway (Machiya et al., 2010) induced a
significant increase in phosphorylated a-Syn in human
neuroblastoma, suggesting that phosphorylation regulates the
a-Syn degradation.PROPAGATION OF ALPHA-SYNUCLEIN:
EVIDENCE AND CONSIDERATIONS
Although dopaminergic neurons of substantia nigra seem to be
particularly vulnerable in PD, the examination of PD progression
indicates that a-Syn pathology is not restricted exclusively to this
region. In 2003, Braak et al. postulated the hypothesis that the
progression of a-Syn pathology follows a specific caudo-rostral
pattern through the central nervous system (Braak et al., 2003;
Braak et al., 2004). These authors proposed that the two starting
points of PD pathology were the olfactory bulb and the enteric
nerves, and from them, the damage extends via the olfactory tract
or the vagus nerve, respectively, to other brain regions.
According to this theory, PD can be divided into six stages,
and each of them is characterized by the development of a-Syn
inclusions in specific brain areas, including dorsal motor nucleus
of vagus nerve, raphe nuclei, magnocellular portions of reticular
formation, locus coeruleus, substantia nigra, and cortex
(Killinger and Kordower, 2019). The presence of these
inclusion bodies causes a dysfunctionality of the cells, which is
ultimately responsible for the development of the clinical
symptoms associated with PD (Braak et al., 2003; Braak et al.,
2004). Given that a-Syn is involved in neuronal plasticity, the
functional consequences of its aggregation have been explored at
both the presynaptic and postsynaptic level. A recent study has
shown that neurons derived from human induced pluripotent
stem cells (iPSC) of PD patients that express oligomer-forming
a-Syn mutants (E46K and E57K) display a reduction in
presynaptic protein levels, an impaired anterograde axonal
transport, and structural abnormalities of the axonal and
synaptic compartments (Prots et al., 2018). Moreover, other
studies have shown that a-Syn plays a role in N-Methyl-D-
aspartic acid (NMDA) receptor trafficking, suggesting that a-Syn
has postsynaptic effects. In a transgenic mouse model expressing
C-terminally truncated a-Syn (aa 1-120), an impaired
hippocampal long-term potentiation due to alterations in
dopaminergic transmission and plastic changes in the
composition of NMDA receptors has been reported (Tofaris
et al., 2006; Costa et al., 2012). Electrophysiological recordings
after treating mouse brain slices with a-Syn oligomers show
impaired synaptic transmission and long-term potentiation in
the hippocampus (Martin et al., 2012; Diógenes et al., 2012). In
vivo amperometry recordings in rodents injected with a-Syn
PFFs in combination with AAV-mediated overexpression of a-
Syn reveal a reduction in dopamine release and reuptake rates in
the s t r i a tum (Thakur e t a l . , 2017) . Recent ly , an
electrophysiological analysis from slices from a-Syn PFFs-
injected mice has shown that a-Syn reduces NMDA receptor-
mediated synaptic currents and impairs long-term potentiation
in the striatal medium spiny neurons (Durante et al., 2019).April 2020 | Volume 11 | Article 356
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in embryonic grafted neurons in PD patients, suggesting that a-
Syn can spread from the host to the graft neurons (Kordower
et al., 2008). The a-Syn protein has been detected in
cerebrospinal fluid, and blood plasma of both PD and healthy
subjects (El-Agnaf et al., 2003) and, in addition, numerous in
vitro studies have demonstrated that cultured neurons can
secrete a-Syn and take it up from the extracellular space (Luk
et al., 2009; Volpicelli-Daley et al., 2011; Reyes et al., 2015). All
these findings suggest that pathological a-Syn acts as a prion-like
protein that can propagate throughout the brain through cell-to-
cell transmission mechanisms. Moreover, the treatment of
cultured cells with recombinant a-Syn fibrils induces the
aggregation of endogenous a-Syn in insoluble inclusions that
resemble Lewy bodies. These data suggest that PFFs can seed the
recruitment of endogenous a-Syn and induce its pathological
conversion (Luk et al., 2009; Volpicelli-Daley et al., 2011). In
addition to in vitro studies, in the last decade, several animal
models of PD have been developed to study (in vivo) the ability
of propagation of a-Syn protein. These models can be classified
as (a) neural stem cell transplantation into transgenic mice
expressing human a-Syn (Desplats et al., 2009), (b)
administration of brain extracts derived from PD patients
(Recasens et al., 2014) or a-Syn pre-formed fibrils (PFFs;
Chung et al., 2019), and (c) AAV-a-Syn viral particles (Ulusoy
et al., 2013; Ip et al., 2017). Among these, the PFFs and the AAV-
a-Syn viral particle models, which are the subject of this review,
are the most extensively used models to study the a-Syn
pathology and propagation.
Although many studies support the prion-like nature of a-
Syn and show that its propagation determines the temporal
course of the disease, some observations have recently
challenged this theory. The Braak staging is neither a proof
nor an argument of the spreading hypothesis, it might be rather
that certain subsets of neurons are affected by Lewy bodies much
earlier than others and that, therefore, the intraneuronal lesions
evolve sequentially (Walsh and Selkoe, 2016). Another clinical
observation that has questioned the pathogenic spread
hypothesis is that only a minority of grafted neurons in
patients with advanced PD exhibited Lewy body-like
inclusions, and their presence appeared to have little functional
consequences for neurons that survived for long periods of time
(Kordower et al., 2008; Cooper et al., 2009; Hallett et al., 2014). In
this context, a new possibility raised is that a selective
vulnerability of specific neuronal populations to certain adverse
stimuli, such as neuroinflammation, contributes to the
propagation of a-Syn (Walsh and Selkoe, 2016). Misfolded a-
Syn can trigger the activation of microglia. Likewise, activated
microglia can enhance the aggregation and spreading of a-Syn,
creating a positive feedback loop between inflammation and a-
Syn aggregation. Both phenomena are interconnected, and this
interaction plays a key role in the pathogenesis of PD. Therefore,
it remains unclear whether a-Syn aggregation is a cause or a
consequence of inflammation. A recent study suggests that
activation of microglia with toxic cytokine release, such as
caspase-1 and calpains, plays a critical role in promoting theFrontiers in Pharmacology | www.frontiersin.org 4misfolding of native a-Syn and in the spread of misfolded a-Syn
in PD (Olanow et al., 2019). The two proposed possibilities, the
prion-like hypothesis and the selective vulnerability hypothesis,
are not mutually exclusive, and a combination of both
hypotheses might occur. It is noteworthy that in the PFFs
models, microglial activation might appear as resulting from
an immune reaction due to the inoculation of foreign a-Syn
fibrils. Indeed, it has been shown that striatal injection of a-Syn
PFFs but not monomers in WT mice can trigger neuro-
inflammation by increasing peripheral immune cells
infiltration in the CNS (Earls et al., 2019). Apparently, this
immune reaction would precede the dopaminergic
neurodegeneration (Harms et al., 2017) but, it cannot be
excluded that the magnitude and the efficacy of the immune
reaction can also modulate the spread of the pathology observed
as it was recently suggested by (Earls et al., 2020).
Another crucial question that is not clear is whether the
spreading of a-Syn is a driving factor for neuronal degeneration
and progression of PD, or if it is an epiphenomenon that appears
as a result of other alterations, such as lysosomal dysfunction
(Killinger and Kordower, 2019). Despite the unequivocal
evidence of the presence of Lewy body-like inclusions and the
ability of a-Syn to propagate in animal models, why
dopaminergic neurons of SNc should be particularly vulnerable
to propagated aggregates of a-Syn remains uncertain. The lack of
a-Syn deposits in some PD, patients (Gaig et al., 2009; Johansen
et al., 2018) has led some authors to the belief that the presence
and spread of Lewy-type aggregates are not sufficient to explain
the dysfunction and loss of neurons and the development of
parkinsonian symptoms.
Lysosomal dysfunction impairs the ability to remove toxic
aggregates, which increases the probability of a-Syn aggregation
and spreading (Klein and Mazzulli, 2018). a-Syn is degraded
through the lysosome in physiological conditions, so some
perturbations in lysosomal functions can affect the a-Syn levels
(Martinez-Vicente et al., 2008). Likewise, a-Syn aggregates might
impair the autophagic-lysosomal pathway function (Xilouri
et al., 2013a), establishing a reciprocal relationship. The
accumulation of a-Syn reduces lysosomal degradation capacity
by d i s rup t ing hydro l a s e s t r a ffi ck ing , such a s o f
glucocerebrosidase 1 (GCase1), from the endoplasmic
reticulum to the lysosome (Mazzulli et al., 2011; García-Sanz
et al., 2017; García-Sanz et al., 2018). Currently, mutations in the
GBA1 gene are the main genetic risk factor for PD. The GBA1
gene encodes for GCase1, a lysosomal enzyme responsible for
degrading the lipid glucosylceramide into ceramide and glucose
(Do et al., 2019). GBA1 mutations result in reduced enzymatic
activity that leads to the accumulation of glucosylceramide and
of cholesterol and its esters in lysosomes, which can compromise
lysosomal function and promote a-Syn aggregation, creating a
bidirectional loop (Schapira, 2015). Previous studies from our
laboratory have shown that fibroblasts derived from PD patients
with the GBA1 mutation accumulate cholesterol in lysosomes
and present multilamellar bodies (García-Sanz et al., 2017;
García-Sanz et al., 2018). Also, membrane structures
resembling lysosomes and autophagosomes have been found inApril 2020 | Volume 11 | Article 356
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2019), suggesting that the alteration of these organelles might
contribute to the formation of Lewy bodies.
In addition to GBA1mutations, numerous PD-related genetic
variants have been identified in several genes involved in the
autophagic-lysosomal pathway including Parkin, PINK1, DJ-1,
LRRK2, ATP13A2, or VPS35 (Klein and Westenberger, 2012).
Some of these genes encode lysosomal enzymes/proteins (e.g.
ATP13A2), whereas others correspond to proteins that are
involved in the transport to the lysosome (e.g. VPS35),
mitophagy (e.g. Parkin , PINK1 , and DJ-1), or other
autophagic-related functions (e.g. LRRK2; Gan-Or et al., 2015).
Mutations in these genes are directly related to autosomal
-dominant or recessive- PD forms or may contribute to
increase PD susceptibility.
Propagation and aggregation of a-Syn is an important
molecular mechanism that contributes to PD progression.
However, this event might require other factors to promote the
pathological development of the disease. Mitochondrial
dysfunction, oxidative stress, failure of the lysosomal
autophagy and ubiquit in-proteasome systems, and
neuroinflammation have been recognized as potential triggers
of the misfolding of a-Syn, the spread of pathology, and the
progression of PD. Precisely, Lewy bodies are composed by
fragmented organelles including mitochondria, lipid
membranes, lysosomal structures as well as other proteins
involved in the degradation systems such as ubiquitin and p62/
SQSTM1, suggesting a potential role of damaged and disrupted
organelles in the formation of a-Syn inclusions (Shahmoradian
et al., 2019). All these factors depend on the age, genetic
background, and environment to which each individual is
exposed. Likewise, the misfolding of a-Syn and its consequent
aggregation might cause several alterations, such as
mitochondrial dysfunction, endoplasmic reticulum stress,
impairment of protein clearance pathways, disruption of
biological membranes, and synaptic dysfunction (reviewed in
Roberts and Brown, 2015). Future research should focus on
determining which events lead first to the development of
pathology and understand how the different mechanisms
involved interact with each other.ANIMAL MODELS OF PD BASED ON
ALPHA-SYNUCLEIN
Given the close relationship between a-Syn aggregation and
PD pathology, a wide variety of PD animal models has been
generated in recent years. This review includes a detailed
analysis of models based on the inoculation of a-Syn PFFs
and models based on overexpression of a-Syn by recombinant
adeno-associated viral vectors (rAAV), giving special interest
to the differences observed between these two models. These
observations are based on results obtained by our group and
which are in line with the findings of previous studies.Frontiers in Pharmacology | www.frontiersin.org 5Injection of a-Syn Pre-Formed Fibrils or
Pathological Extracts
One of the approaches that have been developed to study the
propagation of a-Syn is the intracerebral or systemic
administration of either a-Syn pre-formed fibrils (PFFs) or
brain extracts containing Lewy bodies and a-Syn derived from
PD patients or transgenic mice exhibiting a-Syn pathology. PFFs
are generated in vitro from recombinant a-Syn monomers.
Subsequently, the aggregation of monomers into fibrils is
induced and the fibrils are sonicated to generate short fibrils
wh i c h a f t e r i n j e c t i on , t r i g g e r t h e a g g r e g a t i on ,
hyperphosphorylation and ubiquitination of endogenous a-Syn
(Patterson et al., 2019). Intracerebral injection of a-Syn PFFs has
been extended to rodents, both mice (Luk et al., 2012a; Masuda-
Suzukake et al., 2013; Karampetsou et al., 2017; Milanese et al.,
2018; Okuzumi et al., 2018; Patterson et al., 2019) and rats
(Paumier et al., 2015; Harms et al., 2017; Thakur et al., 2017;
Duffy et al., 2018b; Durante et al., 2019) and non-human
primates (Shimozawa et al., 2017; Chu et al., 2019). PFFs have
been mainly injected in the striatum (Luk et al., 2012a; Paumier
et al., 2015; Karampetsou et al., 2017; Shimozawa et al., 2017;
Duffy et al., 2018b; Milanese et al., 2018; Okuzumi et al., 2018;
Chu et al., 2019; Durante et al., 2019; Patterson et al., 2019), the
substantia nigra (Masuda-Suzukake et al., 2013; Harms et al.,
2017) and the cortex (Luk et al., 2012b). Similarly, the
inoculation of purified brain extracts from PD patients or
transgenic mice containing pathological a-Syn has been
performed in rodents and non-human primates (Luk et al.,
2012b; Recasens et al., 2014). Most of these models have
succeeded in producing the accumulation and aggregation of
phosphorylated a-Syn (pa-Syn), the progressive degeneration of
dopaminergic neurons, a significant reduction in striatal
dopamine levels, neuroinflammation, and the development of
motor deficits (Recasens et al., 2014; Paumier et al., 2015;
Karampetsou et al., 2017; Shimozawa et al., 2017; Patterson
et al., 2019). It is well described that intracerebral inoculation
of PFFs leads to the formation of pa-Syn-immunoreactive
aggregates that are distributed both in the soma and neuronal
processes. a-Syn inclusions exhibit different morphological
features that resemble human Lewy bodies: from granules with
cytoplasmic staining to compact and rounded structures with
dark staining that fills entirely cells (Luk et al., 2012a; Paumier
et al., 2015; Chu et al., 2019). Some studies have shown that these
aggregates commonly colocalize with key markers of Lewy
bodies , including ubiquit in and p62/proteasome 1
(Wakabayashi et al., 2013), and they are thioflavin S-positive
and proteinase K-resistant, indicating that they share common
properties with human Lewy bodies (Paumier et al., 2015; Chu
et al., 2019). Our group has observed the presence of pa-Syn-
immunoreactive structures with similar morphological
characteristics at 12 weeks after intrastriatal inoculation of
human wild-type aSyn PFFs in the SNCA-OVX transgenic
mouse model (Janezic et al., 2013; Figure 1).
Also, these models have shown that pathological a-Syn can
spread from the injection site to other anatomicallyApril 2020 | Volume 11 | Article 356
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transport (Figure 4). The fibrils are picked up by the nerve
terminals of dopaminergic neurons, travelling from them to the
cell body located in the substantia nigra pars compacta. At early
stages after the injection of PFFs, a-Syn inclusions are visible in
regions close to the injection site, but over time the inclusions
can be detected in other areas, including locus coeruleus, SNc,
thalamus, hypothalamus, amygdala, and neocortex, confirming
that there is a time-dependent propagation of a-Syn pathology
(Luk et al., 2012a; Luk et al., 2012b; Paumier et al., 2015; Duffy
et al., 2018b; Patterson et al., 2019). Some studies have reported
that unilateral injection of PFFs leads to the accumulation of pa-
Syn in the hemisphere contralateral to the injection (Luk et al.,
2012b; Polinski et al., 2018). Indeed, we also observed small and
faint pa-Syn-positive fibers into the contralateral hemisphere.
These fibers are mainly found into the striatum, but also into
motor cortex, amygdala and substantia nigra (Figure 2). The
presence of a-Syn-immunoreactive inclusions in the fibers of theFrontiers in Pharmacology | www.frontiersin.org 6corpus callosum and anterior commissure, which extend
bilaterally, might explain the interhemispheric transmission of
a-Syn pathology.
Notably, the injection of a-Syn PFFs in transgenic null mice
for murine Snca (i.e. a-Syn KO mice) does not lead to the
formation of a-Syn inclusions or degeneration; an observation
which supports that endogenous a-Syn is required for the
development of the pathology (Luk et al., 2012b; Kim et al.,
2019). Recasens et al. (2014) have shown that the cytoplasmic
accumulation of a-Syn detected in the SNc of mice injected with
Lewy body extracts at 4 months post-injection could be
exclusively attributed to endogenous a-Syn, since at this time,
the exogenous a-Syn could not be detected. These findings
suggest that fibrils of a-Syn act as a template to convert the
endogenously expressed a-Syn into pathological aggregates
(Recasens et al., 2014).
Nevertheless, it is important to highlight the great variability that
exists in these models because the injection site, the amount andFIGURE 1 | a-Syn aggregation 3 months after intrastriatal a-Syn PFFs injection. (A, B). Representative photomicrographs of pa-Syn-stained sections of the motor
cortex (Mrt Ctx), striatum (STR), amygdala (Amyg), and substantia nigra (SN). (C). High magnification images show the presence of pa-Syn. Scale bar: 100 µm (C,
upper panel) and 50 µm (C,lower panel). PFFs, pre-formed fibrils.April 2020 | Volume 11 | Article 356
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influence the development of neuropathology. Regarding the
injection site, in most of the studies the a-Syn PFFs have been
injected into the striatum because it is a large area with easy access.
The precision required to inject PFFs is critical given that the fibrils
do not spread efficiently through tissues, so adequate inoculation at
the site of interest is important. Interestingly, it has been
demonstrated that the injection of a-Syn PFFs into the substantia
nigra of mice leads to a restriction of the pathological a-Syn
expression around this brain area (Masuda-Suzukake et al., 2014)
and does not induce a dopaminergic degeneration even 15 months
after PFFs inoculation (Masuda-Suzukake et al., 2013). In addition,
the genetic background of rodents can also influence the severity
and the extent of the spreading of Lewy body-like pathology in these
models. Intrastriatal injection of mouse a-Syn PFFs into different
mice strains leads to differences in the severity of the a-Syn-induced
pathology (Luk et al., 2012a).
Another important consideration of this model is the
concentration and type of PFFs injected. Given that the in
vitro generation of PFFs occurs under different conditions (i.e.
pH, temperature, ionic strength), the sonicated a-Syn PFFs are
heterogenous in nature and have different conformational
features and biological effects (i.e. different aggregation pattern,
propensity to propagate, seeding ability and/or toxicity). Rodents
injected with different PFFs strains manifest different
pathological severity and behavioral phenotypes, reflecting the
great variability of the results, especially among different research
studies (Peelaerts et al., 2015; Polinski et al., 2018; Chung et al.,Frontiers in Pharmacology | www.frontiersin.org 72019). A recent study in which a-Syn PFFs have been injected
into the mouse gastric wall shows that mice developed a-Syn-
immunoreactive aggregates in the dorsal motor nucleus at 45
days post-inoculation, but no propagation of pa-Syn aggregates
beyond of the dorsal motor nucleus of the vagus nerve was
observed 12 months after inoculation (Uemura et al., 2018).
These findings support that each a-Syn strain has a different
potency for inducing the propagation. In addition, the animal
species from which the a-Syn is derived seems to be critical.
Although human and mouse a-Syn share 95% sequence identity,
their ability to induce the formation of the inclusions seems to
differ. Injection of mouse PFFs into the duodenal and pyloric
muscularis layers of mice leads to the pathological accumulation
of a-Syn in the SNc at 3 months post-injection, while the
injection of human PFFs does not cause a-Syn accumulation
in the SNc at the same time point (Kim et al., 2019). Moreover,
previous studies have shown that human PFFs injection leads to
slower propagation of a-Syn pathology compared to the
injection of mouse PFFs (Rey et al., 2016). According to this
finding, the formation of aggregates is more efficient if the PFFs
and endogenous a-Syn are from the same species (Fares et al.,
2016). Moreover, some studies have used modified forms of a-
Syn PFFs, for example phosphorylated S129 fibrils or N- and C-
terminally truncated forms. Mice injected with phosphorylated
PFFs exhibited more a-Syn inclusions in the SNc than mice
injected with wild type a-Syn PFFs (Karampetsou et al., 2017).
According to the Braak hypothesis, the PD pathology is
initiated in two independent sites: the gastrointestinal tract andFIGURE 2 | a-Syn expression in the contralateral side to the injection of a-Syn PFFs. Representative photomicrographs of pa-Syn-stained sections of the striatum
of control mice or mice injected with PFFs. Scale bar: 50 µm. PFFs, pre-formed fibrils.April 2020 | Volume 11 | Article 356
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understand the mechanisms by which the pathologic a-Syn
spread through the brain from these two starting sites, a-Syn
PFFs have been administered through peripheral routes (i.e.,
intramuscularly and intravenously), and in the olfactory bulb.
Recent studies demonstrate that the injection of a-Syn PFFs in
the muscular layers of pylorus and duodenum produces a-Syn
aggregation and a significant progressive degeneration of
dopaminergic neurons. The accumulation of pa-Syn in the SN
at 7 months post-injection coincides with a reduction of TH- and
Nissl-positive cells in this region. In contrast, at 1 and 3 months
after injection, there is no significant loss of TH- or Nissl-positive
cells. Accompanying the loss of dopaminergic neurons, a
reduction of tyrosine hydroxylase immunoreactivity in the
striatum is observed at 7 months and, much more at 10
months after PFFs injection, coinciding with the appearance of
pa-Syn aggregates in this area. Also, high-performance liquid
chromatography analysis to measure dopamine concentration
indicates that striatal dopamine levels are significantly reduced at
3 months post-injection (Kim et al., 2019). These mice develop
motor, and non-motor PD symptoms, including psychiatric
behavioral and olfactory dysfunction (Kim et al., 2019) and
gastrointestinal dysfunction (Challis et al., 2020). In addition,
these studies demonstrated that the vagus nerve and endogenous
a-Syn are required for the gut-to-brain transmission of
pathologic a-Syn because truncal vagotomy was performed
prior to inoculation of PFFs (Uemura et al., 2018; Kim et al.,
2019) and the PFFs injection in the Snca null mice (Kim et al.,
2019) prevents the spread of pathologic a-Syn to the brain.
Similarly, another recent study has shown that intrastriatal
injection of a-Syn PFFs induces the Lewy body-like pathology
within the enteric nervous system of wild type mice (Earls et al.,
2019). Likewise, other studies have shown that nigral
overexpression of rAAV-a-Syn in rats produces concomitant
alterations on the enteric nervous system—accumulation of a-
Syn deposits (Ulusoy et al., 2017) and a loss of enteric neurons
and changes in the gut microbiome (O'Donovan et al., 2020),
which reflects that a-Syn pathology in the brain may impact on
the gastrointestinal system and that the gut-to-brain
communication via the vagus nerve may underlie the path of
pathology progression. In other studies, a-Syn PFFs have been
injected into the olfactory bulb, which produces an accumulation
of pa-Syn in different areas distant to the injection site, which
shows that there is a spatial and multi-synaptic progression of a-
Syn pathology over time. Moreover, those studies showed
degeneration and olfactory dysfunction (Rey et al., 2016; Rey
et al., 2018), so these models can be used to reproduce prodromal
PD and test therapies designed to slow or halt the development
of PD.
Given that idiopathic PD is not strictly associated with an
increase in the a-Syn levels, as opposed to PD associated with
duplications and triplications of the SNCA gene, an environment
in which the levels of endogenous a-Syn are physiological would
more faithfully recapitulate the non-genetic forms of PD (Duffy
et al., 2018a). The a-Syn PFFs models, in contrast to those based
on overexpression of a-Syn (viral vector-based and transgenicFrontiers in Pharmacology | www.frontiersin.org 8models), represent an approach in which the pathology is
induced in a context of physiological levels of endogenous a-
Syn (Chung et al., 2019). Thus, these models are especially useful
for assessing the effect of pathological a-Syn injected
exogenously on the aggregation of endogenous a-Syn, and
neuronal function, and to evaluate the resultant parkinsonian
phenotype. Moreover, PFFs models are considered as valuable
tools to develop and test therapies based on preventing the
formation of a-Syn inclusions and their spreading at the early
stages of the disease. While common features are well
reproducible among the different groups working on this
model, a certain degree of variability still exists between the
results. Establishing standard protocols for the preparation of
PFFs can improve the reproducibility of the results obtained.
Additional experiments would be helpful to understand the best
conditions to achieve the most efficient and robust phenotype
(e.g. concentrations of PFFs, site of injection, and comparison
across animal species and strains). Another important
consideration when using the a-Syn PFFs model is to
established whether or not recombinant a-Syn PFFs are
identical to the species of a-Syn present in the pathology of
human PD patients (Polinski et al., 2018).
Overexpression of a-Syn Mediated by
rAAV
Another alternative to model PD is the a-Syn overexpression by
recombinant adeno-associated virus vectors (rAAV). rAAV are
an efficient vehicle for gene delivery in the brain area of interest
and offer some characteristics that favor their use in modeling
PD. rAAV efficiently transduce various cell types, confer long-
lasting transgene expression, and can transduce dividing and
non-dividing cells in the absence of an immune reaction
(Pignataro et al., 2018). Given that neurons are post-mitotic
cells, the capacity of rAAV to transduce non-dividing cells is
crucial in the context of neurodegenerative disease. rAAV are
smaller particles than lentivirus, which gives them the advantage
of spreading efficiently within tissues, being a good choice for
tissue infection. Another advantage of their small size is that
many more rAAV-viral particles can be injected in the same
volume compared to lentiviral particles, resulting in a much
greater functional titer per injected volume. In addition, rAAV
rarely integrate into the host genome, which reduces the
occurrence of mutagenesis. This is crucial since random
integration of the vector into the host DNA can lead to both
loss- and gain-of-function mutations that might alter cell
functionality and homeostasis (Albert et al., 2017).
Overexpression of wild type a-Syn or PD-associated mutants
(A53T or A30P a-Syn) utilizing rAAV leads to a progressive loss
of dopaminergic neurons in the SNc, a loss of dopamine
terminals in the striatum (Koprich et al., 2010; Koprich et al.,
2011; Oliveras-Salvá et al., 2013; Bourdenx et al., 2015; Caudal
et al., 2015; Lu et al., 2015; Ip et al., 2017), and a reduction of
striatal dopamine content (Koprich et al., 2011; Ip et al., 2017).
However, the extent of neurodegeneration achieved with the
rAAV model is variable among the different studies. Several
serotypes, promoters, a-Syn species, doses, and time-course afterApril 2020 | Volume 11 | Article 356
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parkinsonian phenotype achieved. rAAV-a-Syn expression leads
to the accumulation of pa-Syn. Unlike models based on the
administration of a-Syn PFFs, in these models, the a-Syn-
immunoreactive structures are commonly nuclear with a small
and punctate appearance. Some studies have demonstrated that
these structures are proteinase-K resistant (Koprich et al., 2010;
Taschenberger et al., 2012; Lu et al., 2015; Ip et al., 2017) or urea-
resistant (Oliveras-Salvá et al., 2013), but they do not reproduce
the morphological features of human Lewy bodies. Our group
have found that the overexpression of E46K human a-Syn
mediated by rAAV2/9 in the striatum leads to the
accumulation of multiple pa-Syn-immunoreactive structures in
striatal cells, most likely in medium spiny projection neurons
because we observe a diffuse staining of pa-Syn in the terminals
in the projection fields (the globus pallidus and substantia nigra
reticulata) at 12 weeks after rAAV injection (Figure 3).
According to previous studies (Koprich et al., 2010; Ip et al.,
2017), the pa-Syn-immunopositive structures are small, with a
rounded appearance. Although several transgenic mice lines
expressing E46K a-Syn have been generated (Emmer et al.,
2011; Nuber et al., 2018), it is the first time that E46K human
a-Syn form is overexpressed by viral vectors in mice. In the cell
body, a-Syn aggregates are located in the nucleus while in the
projection fields are in the axon terminals. We find that pa-Syn
expression is maintained within the striatal medium spiny
neurons, travelling from the cell body to the terminals, with an
anterograde transport, but we do not observe a transsynaptic
transmission between neurons (Figure 4). These observations
suggest that rAAV-a-Syn expression does not constitute a
propagation model of a-Syn as it is observed with the PFFs
model, so further investigations are needed to understand the
pathological mechanism of excessive amount of a-Syn coming
from external source and those that are endogenously produced.
In the rAAV-a-Syn model, the presence of pa-Syn inclusions
in the nigrostriatal system is concomitant with a significant loss
of nigral dopaminergic neurons and the reduction in tyrosineFrontiers in Pharmacology | www.frontiersin.org 9hydroxylase immunoreactivity in the striatum. Overexpression
of wild type or A53T human a-Syn induces a progressive loss of
dopaminergic neurons in the SN over time (Oliveras-Salvá et al.,
2013). At 5 days post-injection, no degeneration was observed.
The dopaminergic cell loss in the SN increased from 57% at 4
weeks after injection to 82% at 8 weeks for wild type a-Syn; and
from 51% at 4 weeks after injection to 59% at 8 weeks for A53T
a - S yn . S im i l a r t o t h e ob s e r v a t i on f o r t h e SN ,
immunohistochemical staining for TH in the striatum revealed
a gradual reduction of TH expression over time (Oliveras-Salvá
et al., 2013). The maximum of pa-Syn-positive cells in the SN is
reached at 4 weeks post-injection when neurodegeneration
begins to be evident (Oliveras-Salvá et al., 2013). However, in
absence of pa-Syn aggregates, i.e. when animals are injected with
empty viral particles (Koprich et al., 2010; Ip et al., 2017) or in
the contralateral injection side (Oliveras-Salvá et al., 2013),
neurodegeneration is not observed.
Some studies show that rAAV-a-Syn expression causes the
development of motor alterations, such as an increased
apomorphine or amphetamine-induced rotation, defects in the
stepping test or increased forepaw asymmetry in the cylinder test
(Kirik et al., 2002; Decressac et al., 2011; Koprich et al., 2011;
Decressac et al., 2012; Gaugler et al., 2012; Gombash et al., 2013;
Oliveras-Salvá et al., 2013; Bourdenx et al., 2015; Caudal et al.,
2015; Ip et al., 2017). These motor deficits appear several weeks
after injection in animals with a significant loss of
dopaminergic neurons.
In the rAAV-a-Syn models, the transgene expression is
dependent on the serotype, the promoter, the injection site,
and the titer of rAAV. The serotype rAAV2 is the most
extensively used to date, probably because its production and
purification methods are well-established (Van der Perren et al.,
2014). However, there are some limitations associated with the
rAAV2 serotype. First, rAAV2 efficiently transduces neurons but
requires high doses; second, rAAV2 can induce a weak immune
response in human hepatocytes (Mingozzi and High, 2013). A
novel generation of viral particles has recently been produced;FIGURE 3 | a-Syn aggregation 3 months after rAAV-E46K viral particle injection. Representative photomicrographs illustrating the expression of pa-Syn in the
striatum (STR), globus pallidus (GP), and substantia nigra (SN). Scale bar: 500 µm.April 2020 | Volume 11 | Article 356
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associated with the rAAV2 capsid. Indeed, rAAV2/1, rAAV2/5,
rAAV2/6, rAAV2/7, and rAAV2/8 exhibit a higher transduction
efficiency than the rAAV2 in the nigrostriatal pathway (Taymans
et al., 2007; McFarland et al., 2009b; Ulusoy et al., 2012; Oliveras-
Salvá et al., 2013).
The efficiency of transgene expression is also determined by
the design of the vector construct, and the promoter used to
control the transgene expression. The most common promoters
used are hybrid cytomegalovirus (CMV), chicken b-actin (CBA),
phosphoglycerate kinase (PGK), and human synapsin I (Syn-1).
These promoters provide high levels of transgene expression. In
addition, some studies use post-transcriptional regulatory
elements to improve the transgene expression, such as
woodchuck hepatitis virus posttranscriptional regulatory
element or polyadenylation sequence (McFarland et al., 2009a;
Koprich et al., 2010; Koprich et al., 2011; Gaugler et al., 2012;
Gombash et al., 2013; Oliveras-Salvá et al., 2013; Lu et al., 2015).
Determination of viral titer after its production and
purification is a critical factor in defining the transduction
efficiency. In contrast to a-Syn PFFs models, the levels of a-
Syn achieved after transduction with rAAV-a-Syn typically
exceed those found in idiopathic PD or even in PD associated
with SNCA multiplications (Duffy et al., 2018a), despite that the
phenotype severity depends on the viral dose injected (Oliveras-
Salvá et al., 2013). However, although high levels of a-Syn lead to
a more robust phenotype, this does not adequately reflect what
happens in parkinsonian patients. Additional studies are
required to determine the optimal conditions (serotype,
promoter, and viral titer) to improve the ability of this modelFrontiers in Pharmacology | www.frontiersin.org 10to recapitulate the human PD. However, although the
modification of these factors may help to potentiate the PD
phenotype, considering other factors, such as the expression of
endogenous a-Syn or the nature of injected a-Syn, are necessary
to reproduce the complexity of human disease in rodents.
Several parameters, including the species, the strain, and the
age of animals used, influence the development of pathology.
Although most studies have used rats (Kirik et al., 2002; Koprich
et al., 2010; Decressac et al., 2011; Koprich et al., 2011; Gaugler
et al., 2012; Gombash et al., 2013; Caudal et al., 2015; Rocha et al.,
2015; Thakur et al., 2017; O'Donovan et al., 2020), the model has
also been adapted to mice. This opens a wide range of
possibilities due to the greater availability of knockout and
transgenic mice, which could be used to assess whether certain
genes protect or enhance neurodegeneration. Viral a-Syn
overexpression in L444P GBA1 mice produces a greater loss of
dopaminergic neurons in GBA1 than wild type mice, suggesting
that GBA1 mutations enhance the vulnerability of dopaminergic
neurons induced by a-Syn (Migdalska-Richards et al., 2017). In
PINK1 knock out mice, overexpression of a-Syn in the
substantia nigra resulted in enhanced dopaminergic
degeneration as well as high levels of phosphorylated a-Syn,
suggesting that the loss of PINK1 leads to an increased sensitivity
to a-Syn-induced neuropathology (Oliveras-Salvá et al., 2014).
The injection of rAAV-mediating human a-Syn overexpression
in knock out mice for synapsin III (Syn III) shows that silencing
of Syn III could prevent the a-Syn aggregation (Faustini et al.,
2018). Moreover, the genetic background of animals is important
in response to a-Syn overexpression. Human a-Syn
overexpression produced a larger decrease of dopaminergicA
B
FIGURE 4 | Scheme showing the propagation pattern of a-Syn in PFFs and AAV models. The colored areas represent the brain areas where we find pa-Syn
expression after (A) a-Syn PFFs inoculation or (B) AAV-a-Syn administration. Created with: BioRender.comApril 2020 | Volume 11 | Article 356
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strains (Sprague-Dawley and Wistar) displayed different
susceptibility to ha-Syn overexpression (Bourdenx et al., 2015).
A recent study shows that deficiency of CX3CR1 receptor in mice
(Cx3cr1- / -) exacerbates the neurodegeneration and
neuroinflammation induced by overexpression of A53T human
a-Syn, reflecting the importance of genetic background (Castro-
Sánchez et al., 2018). The age of the animals also affects the
vulnerability of dopaminergic neurons to a-Syn. Overexpression
of human a-Syn into old rats produced a more robust loss of
dopaminergic neurons than into young rats (Salganik et al.,
2015). Also, a-Syn levels increase with age in monkeys and
humans (Chu and Kordower, 2007), so the parkinsonian
phenotype might be aggravated in aged mice.
In general, the rAAV-a-Syn are directly injected into the SNc
to transduce dopaminergic neurons of the nigrostriatal system.
Taking into consideration the special characteristics of
dopaminergic neurons of the substantia nigra, that are
particularly vulnerable to stress (Bolam and Pissadaki, 2012), it
is important to include appropriate controls to specifically
determine the neuronal damage and dysfunction caused by a-
Syn overexpression. It is also crucial to analyze whether the
control proteins (e.g., GFP) or empty vectors are toxic to the
dopaminergic neurons (Albert et al., 2017). Although the
immune response produced by rAAV in the brain is minimal,
the extent of the defense response after rAAV injection must be
evaluated. Some studies have demonstrated that the injection of
rAAV carrying GFP results in a significant loss of dopaminergic
neurons (Klein et al., 2006; Koprich et al., 2011; Landeck et al.,
2017). These findings demonstrate the need to use proper
controls to ensure the a-Syn specificity on the degeneration of
dopaminergic neurons.
One important consideration of these models is that the a-Syn
pathology is exclusively restricted to neurons transduced by rAAV
to express a-Syn. There is no evidence of the transmission of the
pathology to other non-transduced neurons despite the expression
of endogenous a-Syn. Another significant drawback is that
individual stereotaxic injection of rAAV might cause a wide
variety in the expression pattern of a-Syn between animals, which
makes it difficult to obtain robust and reproducible results. Morever,
the injections into the SNc are technically difficult, especially in the
mouse brain due to its small size, so high precision in the stereotaxic
procedure is required to minimize the inter-animal variability
(Volpicelli-Daley et al., 2016).
Overexpression of a-Syn mediated by rAAV represents a
valuable tool to induce progressive degeneration of
dopaminergic neurons, accompanied by the development of a-
Syn inclusions in these neurons. Although the progression of
pathological changes observed in rAAV-a-Syn models is faster
than in PD patients, the time-course of these changes is sufficient
to observe the different stages defined in PD patients (pre-
symptomatic, early symptomatic, and advantage stage), which
facilitates the identification of new therapeutic targets (Decressac
et al., 2012). These models are especially useful to study how a-
Syn accumulation and aggregation contributes to neuronal
degeneration and its consequences, such as motor or cognitiveFrontiers in Pharmacology | www.frontiersin.org 11impairment. The use of these models has also been extended to
develop and evaluate potential therapies aimed at reducing the
aggregation of a-Syn and prevent against neurodegeneration
induced by a-Syn (Decressac et al., 2013; Xilouri et al., 2013b;
Rocha et al., 2015).CONCLUDING REMARKS
More than two decades ago, a-Syn was identified as the main
component of Lewy bodies. Since then, this protein has become
established as a possible diagnostic biomarker in PD and
therapeutic target. Also, numerous animal models have used
this protein in attempts to reproduce PD. Each animal model
offers specific aspects of the pathology of human PD, although
none of them reproduce all the defining pathological and clinical
features of the disease. The lack of comparable phenotypes
between rodents overexpressing a-Syn or rodents injected with
toxic a-Syn species reflects the difficulty of reproducing PD in
animal models. Therefore, a thorough knowledge of the key
features of these models is essential to choose the model that best
suits the scientific questions that we want to solve. Here, we show
that a-Syn PFFs models are suitable for studying the prion-like
behavior of a-Syn and its propagation through the brain. While
viral a-Syn overexpression models are especially useful to
determine the mechanisms of a-Syn-induced toxicity but do
not allow the study of their prion-like behavior. Despite these
differences, both models are valuable tools for identifying novel
therapeutic targets and the design and evaluation of potential
therapies aimed at reducing the aggregation of a-Syn to alter
disease progression.ETHICS STATEMENT
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